BioSpace News Archive

Antengene Corporation Limited today announced the presentation of five posters at the American Association for Cancer Research Annual Meeting 2023 Meetings (AACR 2023), taking place from April 14th to 19th at the Orange County Convention Center in Orlando, Florida, the United States.

Leinco Technologies (“Leinco”) (St. Louis, MO) today announced the launch of the mAbMods™ chimeric anti-mouse PD1 and PD-L1 recombinant antibodies to target mouse programmed cell death receptor 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) in in vivo functional studies.

AffaMed Therapeutics (“AffaMed”) today announced that China’s National Medical Products Administration (NMPA) has approved AffaMed’s Clinical Trial Application (CTA) to initiate a Phase 3 registrational study in China to investigate the efficacy and safety of DEXTENZA in subjects following ophthalmic surgery.

Precision Optics Corporation, Inc. announced the appointment of medical device and aerospace/defense industry manufacturing veteran, Mahesh Lawande, as the Company’s Chief Operating Officer effective April 24, 2023.

Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced data presentations on two first-in-class programs at the American Association for Cancer Research (AACR) 2023 Annual Meeting held in Orlando, Florida, on April 14–19, 2023.

Imvax, Inc. today announced a poster presentation providing additional mechanistic insights into its Goldspire™ platform based on preclinical studies of its lead product candidate, IGV-001, for the treatment of glioblastoma (GBM).

Innoviva, Inc., a diversified holding company with a portfolio of royalties and other healthcare assets, announced that Nasdaq has halted trading of Innoviva’s common stock.

GlucoTrack, Inc. announced the closing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric small molecule therapies targeting eIF4E, is presenting pre-clinical data today on the company’s advancing eIF4E program for breast cancer in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, FL.

Smart Meter, the number one supplier of remote patient monitoring devices, data, and services, supporting a nationwide network of SmartPartners, announces three new products at the HIMSS Global Conference in Chicago.